The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.95
Bid: 2.90
Ask: 3.00
Change: -0.10 (-3.28%)
Spread: 0.10 (3.448%)
Open: 3.05
High: 3.05
Low: 2.95
Prev. Close: 3.05
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Good Energy says ZapMap expands into mainland Europe

Wed, 13th Dec 2023 21:14

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

British Smaller Cos VCT PLC and VCT 2 - Leeds, England-based venture capital trusts - Confirm the addition of an over-allotment facility of GBP25 million to their subscription offer, following its launch in September. Add that they have received applications approaching GBP60 million so far, with the deadline for applications on March 28, 2024. Notes subscription was initially launched to raise GBP65 million.

----------

Frontier IP Group PLC - London-based intellectual property commercialisation company - Says portfolio company The Vaccine Group has appointed three animal health experts to its advisory board in order to support the scale-up of its herpesvirus-based platform. Says advisory board members are Merck & Co Inc's Christophe Barnier-Quer, as well as Johan Dreesen and Vaughn Kubiak. Neil Crabb, Frontier IP Chief Executive Officer, says: "I am delighted TVG has been able to form an advisory group of such good quality. It is a testament to the potential of the Company, its vaccine platform and pipeline, and I look forward to further developments as TVG's vaccines move towards scale up and full commercialisation."

----------

DeepVerge PLC - Dublin-based environmental and life sciences firm - Says it has made progress in its discussions with potential buyers of assets and intellectual property in its Modern Water and Labskin business units. Adds that it hopes to agree on a sale in January. Says, however, that even if both asset sets are sold, the sales will not be of enough value to avoid closure or administration of the two subsidiaries. Adds that it currently has debts of GBP300,000 and is unsure whether it will have the funds to pay these debts. Says shares expected to be cancelled on December 27.

----------

Good Energy Group PLC - Wiltshire, England-based supplier of 100% renewable power and an innovator in energy services - Says investee company Zapmap, an electric vehicle charge point mapping service, has expanded its market presence to mainland Europe. Says its mapping service is now available in France, Germany, Belgium, the Netherlands and Luxembourg. Says coming months will see Zapmap open features including EV route planning and charging payments. Good Energy Chief Executive Nigel Pocklington says: "Zapmap has made significant progress over the last year as it continues to broaden and deepen its market presence in the UK and now across Europe. It continues to track with the rapidly growing electric vehicle market, which has expanded by 40% in the UK last year with the share of electric vehicles new car registrations increasing in almost all EU countries."

----------

ValiRx PLC - life science company based near Birmingham, England, which is focused on early-stage cancer therapeutics and women's health - Launches placing to raise GBP1.6 million, via the issue of 26.3 million shares at 6.0 pence each. Adds that it will also launch a retail offer at 6.0 pence per retail share. Says retail offer is only open to existing shareholders. Notes that certain directors will also subscribe for 500,000 shares at 6.0p each. Says it will raise GBP1.9 million in total, which will be used to integrate BioBank materials form its asset acquisition from Imagen, as well as research and development.

----------

Creo Medical Group PLC - Chepstow, Wales-based medical device company - Says it has completed the first procedure using Speedboat Ultraslim. Says the product was used for a lower Gastrointestinal tract procedure in the UK, with the first European procedure expected to follow shortly. Speedboat is used to treat gastrointestinal tract diseases, including bowel, stomach and oesophagus cancers. CEO Craig Gulliford comments: "This is yet another landmark moment for Creo Medical. We know what a difference this even smaller device will make in terms of broadening access to advanced energy in endoscopy for a wider pool of clinicians. Speedboat UltraSlim is compatible with all major endoscopes, meaning clinicians can bring advanced energy to their practices, allowing more patients to be treated endoscopically, which avoids surgery and the associated secondary costs and risks."

----------

Macfarlane Group PLC - Glasgow-based supplier of packaging materials - Promotes James Baird to senior independent director.

----------

Asia Strategic Holdings Ltd - Singapore-based developer and operator of consumer businesses located in emerging Asian economies - Agrees amended loan facility with Macan Pte Ltd, increasing its loan to USD4.5 million, from USD3.0 million. Adds that the increase is in order to support its expansion of its school network. Notes that it has agreed to extend the repayment date to December 31 2027. Macan is the largest shareholder of Asia Strategic, representing 32.4%, while Asia Strategic Chief Executive Enrico Cesenni holds 35.1% of the voting rights of Macan.

----------

By Harvey Dorset, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
14 Jun 2018 11:00

WINNERS & LOSERS SUMMARY: Rolls Royce Flies High With Planned Job Cuts

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.----------FTSE 100 - up 2.6%. The jet engine maker said it will cut

Read more
11 May 2018 16:43

Nicholas Slater Increases ValiRx Stake To 4.5% From 2.7% (ALLISS)

LONDON (Alliance News) - ValiRx PLC said Friday Nicholas Slater had almost doubled his stake in life science company, which focuses on cancer treatments, to 4.5% after a transaction on raised his

Read more
4 May 2018 17:08

ValiRx Raises GBP950,000 Through Placing To Progress Pipeline (ALLISS)

LONDON (Alliance News) - ValiRx PLC said Friday it has raised GBP950,000 through the issue of 47.5 million shares at 2.00 pence per share.The clinical stage biotechnology company's down

Read more
25 Apr 2018 13:41

"Major" Milestone As ValiRx's VAL201 Is Granted Patent In EU

LONDON (Alliance News) - Biotechnology company ValiRx PLC said Wednesday its VAL201 compound has been granted a patent in the EU.This, it said, follows a US patent which was granted for a a

Read more
19 Apr 2018 12:41

ValiRx Posts Positive Results From VAL101 Compound Pre-Clinical Trials

LONDON (Alliance News) - ValiRx PLC on Thursday said pre-clinical studies showed that its VAL101 compund has a potential to prevent cancer growth at cellular biochemical and genomic molecule is is

Read more
29 Mar 2018 00:12

UPDATE 1-Argentina Merval index to shrink to 28 companies in Q2

BUENOS AIRES, March 28 (Reuters) - Argentina's benchmark Merval stock index will shrink to 28 component companies in the second quarter, down from 31

Read more
28 Mar 2018 23:11

Argentina Merval index to shrink to 28 companies in Q2

BUENOS AIRES, March 28 (Reuters) - Argentina's benchmark Merval stock index will shrink to 28 component companies in the second quarter, down from 31

Read more
20 Mar 2018 13:55

ValirX Gets US Patent For Proposed VAL201 Cancer Treatment

LONDON (Alliance News) - Biotechnology firm ValirX PLC said Tuesday its VAL201 therapeutic compound has been granted a patent in the US.VAL201, which is currently in is

Read more
19 Mar 2018 12:46

YA II CD Lowers ValiRx Interest To Below 3% Threshold (ALLISS)

LONDON (Alliance News) - Life sciences firm ValiRx PLC said on Monday YA II CD Ltd has cut its stake in the company to below 3%.Prior to last Thursday's YA II CD a

Read more
11 Jan 2017 11:18

ValiRx upbeat on positive VAL201 study results

(ShareCast News) - Clinical stage biotechnology company ValiRx announced positive results in its VAL201 personalised Phase l/II prostate cancer study on Wednesday, adding that with accumulation of safety and tolerability data there is also evidence of disease stabilisation on CT imaging and reductio

Read more
11 Jan 2017 09:01

ValiRx To Expand VAL201 Studies After Positive Results

Read more
3 Nov 2016 11:40

ValiRx reports good progress at Georgia drug trial

(ShareCast News) - Life science company focused on clinical stage cancer therapeutic development, ValiRx, updated the market on the clinical development of its novel cancer treatment drug, VAL401. The AIM-traded firm said ValiSeek, the joint venture between ValiRx and Tangent Reprofiling, was formed

Read more
27 Sep 2016 10:17

ValiRx Interim Loss Widens As It Progresses Drug Pipeline

Read more
28 Jul 2016 08:41

ValiRx Gets Patent Coverage For VAL401 In New Zealand

Read more
26 Jul 2016 09:43

ValiRx Issues Shares To Bracknor For Loan Note Conversion (ALLISS)

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.